Positron Displays PULSE CDC(TM) and
Introduces New Cardiac PET Scanner at the Annual
Meeting of the American Society of Nuclear
Cardiology
Tuesday October 16, 4:34 pm ET
HOUSTON--(BUSINESS WIRE)--Positron Corporation
(OTCBB:POSC
-
News) displayed their PULSE CDC(TM) SPECT
imaging system as well as introduced their new
dedicated Cardiac PET system that is expected to
receive 510k FDA approval in spring 2008 at the
annual meeting of the American Society of Nuclear
Cardiology. The meeting attendees consisted of more
than 1,500 nuclear cardiologists, practice
administrators and technologists with the majority
operating myocardial perfusion imaging with private
cardiology practices.Market research from the
ASNC meeting suggested that the cardiologist market
would readily move to compliment their molecular
imaging offering by adding Positron's cost effective
Attrius system, especially due to the proposed
cardiac PET reimbursement increase (Jan 1, 2008).
Positron is expecting significant demand for
their product since they will be the only vendor
offering an all new PET only molecular imaging
system for less than $600,000 with the primary focus
on cardiology. Positron intends to be the first
company to offer absolute coronary flow reserve
calculations developed by K. Lance Gould, M.D. Dr.
Gould is considered the founder of Cardiac PET
combined with the discovery of flow reserve in human
studies.
Positron Corporation's President, Joseph Oliverio
stated, "The American Society of Nuclear Cardiology
meeting confirmed our internal market research. We
strongly believe that we are in a great position to
be the leader in the rapidly expanding market of
Cardiac PET. We will be the only company that is
focused on bringing to market an affordable
dedicated cardiac PET scanner with superior
technology and disease focused software. We
anticipate receiving our 510k FDA approval in spring
of 2008."
About Positron
Positron Corporation designs, manufactures,
markets and supports advanced cardiac molecular
imaging devices utilizing single photon emission
computed tomography (SPECT) and positron emission
tomography (PET). The company's molecular imaging
systems incorporate patented and proprietary
software and hardware technology for the diagnosis
and treatment of patients with heart disease.
Positron Corporation offers unique combination of
low cost technology and disease specific software
solutions differentiating themselves from all other
medical device manufacturers. Additional information
may be found at
http://www.positron.com and
http://www.is2medical.com.
Forward Looking Statements:
Statements in this document contain certain
forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and the
Securities Exchange Act of 1934, as amended. These
statements are based on many assumptions and
estimates and are not guarantees of future
performance and may involve known and unknown risks,
uncertainties and other factors which may cause the
actual results, performance or achievements of
Positron Corporation to be materially different from
future results, performance or achievements
expressed or implied by such forward-looking
statements. The words "expect," "anticipate,"
"intend," "plan," "believe," "seek," "estimate," and
similar expressions are intended to identify such
forward-looking statements. Our actual results may
differ materially from the results anticipated in
these forward-looking statements due to a variety of
factors, including, without limitation those set
forth as "Risk Factors" in our filings with the
Securities and Exchange Commission.
For further information please contact Positron
Corporation at (281) 492-7100.
Contact:
Positron Corporation
Joseph Oliverio, 281-492-7100
President
Source: Positron
Corporation
Main news page
|
